Take Action
Research Details
Equilibrium Effects of Pharmaceutial Bundling: Evidence from India
Abstract
We study the equilibrium effects of competitive bundling in the context of the Indian pharmaceutical industry. Fixed-dose combinations (FDCs), which bundle two or more drugs in a single pill, account for over 50% of pharmaceutical revenue in India. Using an equilibrium model of drug demand and supply, we show that the price and welfare effects of FDCs are theoretically ambiguous. Empirically, we find that FDCs on average sell at a 28% discount but increase standalone component prices by 3%. New FDCs significantly increase sales of drug bundles. To quantify the welfare effects of FDCs, we estimate the model in the market for Alzheimer’s drugs. We find that FDCs increase consumer surplus by 21% and firm profits by 13% because of significant market expansion and cost savings. Counterfactual analysis shows that applying FDC regulations from the US to India could deter FDC entry and forestall potential welfare benefits.
Type
Working Paper
Author(s)
Shengmao Cao, Chirantan Chatterjee
Date Published
2022
Citations
Cao, Shengmao, and Chirantan Chatterjee. 2022. Equilibrium Effects of Pharmaceutial Bundling: Evidence from India.
LINK READ